

## **REMARKS**

### **Amendments**

The amendment to the specification corrects a typographical error in the statement incorporating related applications, as amended on 22 August 2005. The amendment is supported by the application as filed and introduces no new matter.

A substitute paper-copy sequence listing accompanies this amendment. The amended sequence listing adds the information regarding strand orientation for the nucleotide sequences that was present in the paper-copy sequence listing that was part of the specification as filed. The examiner has identified the omission of this information from the sequence listing as a formal defect in counterpart applications. Although 37 C.F.R. § 1.823 provides that the required components of a sequence listing do not include identification of sense or antisense orientation, applicant is filing this revision to moot the issue here. The revised sequence listing adds no new matter.

A computer-readable copy of the substitute sequence listing is being filed on this date through the Office's electronic submission facility (epave). In compliance with 37 C.F.R. § 1.821(e), the undersigned states that the paper and computer-readable copies of the sequence listing are identical.

### **Election**

In response to the requirement for restriction stated in the Office letter mailed on 24 March 2006, applicant elects group I, claims 70-75 "drawn to a host cell," without traverse. Claims 79-97, corresponding to nonelected groups III, IV, and V, are canceled without prejudice to their presentation in another application.

Claims 76-79, corresponding to nonelected group II, are retained in the case. Applicant understands that pursuant to M.P.E.P. § 821.04(b), the dependent method claims corresponding to this group will be rejoined with the elected product claim from which they depend upon a finding that the product claim is allowable. Applicant specifically requests such rejoinder.

**Conclusion**

Applicant believes that this reply fully responds to the outstanding Office action and requests that the examiner prepare an action on the merits at an early date.

Respectfully submitted,

/David L. Fitzgerald/

David L. Fitzgerald, Reg. No. 47,347  
Attorney for Biogen Idec Inc.

SIDLEY AUSTIN LLP  
1501 K Street, N.W.  
Washington, DC 20005

tel. (202) 736-8818  
fax (202) 736-8711